1276110-36-1

Basic information

• Product Name: 3,5-difluoro-N-(5-(3-(5-methyl-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]-pyridin-6-yl)pyridin-3-yl)benzenesulfonamide
• CAS NO: 1276110-36-1
• Molecular Weight: 468.443
• Mol File: 1276110-36-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3,5-difluoro-N-(5-(3-(5-methyl-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]-pyridin-6-yl)pyridin-3-yl)benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-difluoro-N-(5-(3-(5-methyl-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]-pyridin-6-yl)pyridin-3-yl)benzenesulfonamide(1276110-36-1)
• EPA Substance Registry System: 3,5-difluoro-N-(5-(3-(5-methyl-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]-pyridin-6-yl)pyridin-3-yl)benzenesulfonamide(1276110-36-1)

Safety Data

• Hazardous Substances Data: 1276110-36-1(Hazardous Substances Data)

Upstream product

• 138240-34-3 (E)-N’-(5-bromopyridin-2-yl)-N,N-dimethylformamidine 
• 474709-01-8 3-(6-bromoimidazo[1,2-a]pyridin-3-yl)-5-methyl-1,2,4-oxadiazole 
• 474708-98-0 6-bromoimidazo[1,2-a]pyridine-3-carbonitrile 
• 1148008-72-3 C₈H₇BrN₄O 
• 1072-97-5 5-bromo-2-pyridylamine 

Relevant articles and documents

Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis

Phosphatidylinositol 3-kinase α (PI3Kα) is an important regulator of intracellular signaling pathways, controlling remarkably diverse arrays of physiological processes. Because the PI3K pathway is frequently up-regulated in human cancers, the inhibition of PI3Kα can be a promising approach to cancer therapy. In this study, we have designed and synthesized a new series of imidazo[1,2-a]pyridine derivatives as PI3Kα inhibitors through the fragment-growing strategy. By varying groups at the 3- and 6-positions of imidazo[1,2-a]pyridines, we studied the structure-activity relationships (SAR) profiles and identified a series of potent PI3Kα inhibitors. Representative derivatives showed good activity in cellular proliferation and apoptosis assays. Moreover, these inhibitors exhibited noteworthy antiangiogenic activity.